Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency

American Journal of Kidney Diseases

Volumn 44, Issue 2, 2004, Pages 250-256

  Shigematsu, Takashi ^a   Kazama, Junichiro James ^b   Yamashita, Takeyoshi ^c   Fukumoto, Seiji ^d   Hosoya, Tatsuo ^a   Gejyo, Fumitake ^b   Fukagawa, Masafumi ^e  

^a Jikei University Katsushika Medical Center   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c KIRIN BREWERY CO LTD   (Japan)

^d UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^e KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

1,25 dihydroxyvitamin D3 (1,25D); Fibroblast growth factor 23 (FGF 23); maximum tubular reabsorptive rate of phosphate (TmP GFR); parathyroid hormone (PTH); phosphate; secondary hyperparathyroidism

Indexed keywords

CREATININE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; MONOCLONAL ANTIBODY; PARATHYROID HORMONE; PHOSPHATE; UNCLASSIFIED DRUG; UREMIC TOXIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MINERAL METABOLISM; NEPHRON; PHOSPHATE URINE LEVEL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN FUNCTION; SECONDARY HYPERPARATHYROIDISM; STATISTICAL SIGNIFICANCE; URINALYSIS; URINARY EXCRETION;

ADOLESCENT; ADULT; AGED; CALCITRIOL; CALCIUM; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULONEPHRITIS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; KIDNEY TUBULES; MALE; MIDDLE AGED; NEPHRONS; PARATHYROID HORMONE; PHOSPHATES;

EID: 3242661165     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2004.04.029     Document Type: Article

References (22)

1. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 277:2000;494-498
2. White K.E., Evans W.E., O'Riordan J.L.H., et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 26:2000;345-348
3. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 98:2001;6500-6505
4. Bay X.Y., Miao D., Golzman D., et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 278:2003;9843-9849
5. Saito H., Kusano K., Kinosaki M., et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem. 278:2003;2206-2211
6. Shimada T., Urakawa I., Yamazaki Y., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium-phosphate cotransporter type IIa. Biochem Biophys Res Commun. 314:2004;409-414
7. Weber T.J., Liu S., Indridason O.S., et al. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 18:2003;1227-1234
8. Yamazaki Y., Okazaki R., Shibata M., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 87:2002;4957-4960
9. Jonsson K.B., Zahradnik R., Larsson T., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 348:2003;1656-1663
10. Quarles L.D. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. 285:2003;E1-E9
11. Locatelli F., Cannata-Andia J.B., Drueke T.B., et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant. 17:2002;723-731
12. Larsson T., Nisbeth U., Ljunggren O., et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 64:2003;2272-2279
13. Kazama J.J., Gejyo F., Shigematsu T., et al. Circulating fibroblast growth factor-23 (FGF-23) levels predict the development of secondary hyperparathyroidism in long term dialysis patients. J Am Soc Nephrol. 14:2003;209A. (abstr)
14. Kazama J.J., Kutsuwada K., Ataka K., et al. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron. 91:2002;13-20
15. Gao P., Scheibel S., D'Amour P., et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84 Implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 16:2001;605-614
16. Kazama J.J., Omori K., Higuchi N., et al. Intact PTH assay overestimates 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 19:2004;892-897
17. Fukagawa M., Kazama J.J., Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant. 17:(suppl 10):2002;S2-S5
18. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis. J Bone Mineral Res. 19:2004;429-435
19. Murer H., Biber J. Molecular mechanisms of renal apical Na/phosphate cotransport. Annu Rev Physiol. 58:1996;607-618
20. Yamashita T., Konishi M., Miyake A., et al. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem. 277:2002;28265-28270
21. Shimada T., Muto T., Urakawa I., et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 143:2002;3179-3182
22. Slatopolsky E., Robson A.M., Elkan I., et al. Control of phosphate excretion in uremic man. J Clin Invest. 47:1968;1865-1874